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The US company which owns and markets the controversial PROMETA proprietary 
combination of drugs for methamphetamine dependence funded a rigorous trial by 
independent researchers; the result was a no-better-than-placebo verdict, another 
negative in the search for drugs to counter stimulant dependence.
Summary After cannabis, the powerful stimulant methamphetamine is the most abused 
illicit drug worldwide, with 15–16 million regular users, yet there are no approved 
medications for the treatment of methamphetamine dependence.
A proprietary system of treatment for methamphetamine dependence, the PROMETATM 
protocol, combines medications purported to normalise brain systems altered by chronic 
stimulant use along with psychosocial treatment designed to minimise withdrawal 
symptoms, prevent relapse and reduce cravings. Of the three medications in the 
protocol, flumazenil is the principal element. Among other effects, the drug works via the 
GABA neurotransmitter system to block the action of benzodiazepine tranquilisers and 
sleeping pills. Medically it is used to reverse deep sedation and as an antidote to 
benzodiazepine overdose. A second element is gabapentin, an anti-convulsant which also 
acts on the GABA system and which has been used as an analgesic. It has been reported 
to reduce craving and other subjective effects of cocaine. Last is hydroxyzine 
hydrochloride, an anti-anxiety drug which has been widely used in the management of 
withdrawal from substance dependence.
The featured study was conducted when this protocol was being heavily publicised and 
was subject to a great deal of debate and controversy in drug abuse, investment and 
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news media circles. Proponents were buoyed by anecdotal reports and uncontrolled 
studies, while opponents cited the lack of data from placebo-controlled trials. In just such 
a trial, the study aimed to evaluate the efficacy and safety of this protocol in the 
treatment of methamphetamine dependence. It was funded by the company which owns 
the protocol, which also referred people seeking treatment via its call centre to the 
researchers and trained the researchers in the protocol to ensure their implementation 
matched the company's specification. The company played no other part in the study.
The study recruited adults seeking treatment for methamphetamine abuse or 
dependence and who had used the drug on at least four of the last 30 days. The 120 
eligible for and who agreed to join the study were allocated to one of three clinics which 
offered a 40-day medication regimen beginning with five infusions (at two clinics on an 
inpatient basis) plus 14 weekly sessions of cognitive-behavioural therapy over the 
roughly 15 weeks of the trial. For a randomly selected half of the patients, the medication 
was the PROMETATM protocol; the other half were given identical but inactive placebo 
preparations (except that they too were offered the anti-anxiety agent hydroxyzine 
hydrochloride, not considered a key element of the protocol). The study based its 
findings on the 111 patients who at least began the medication/placebo regimens. 
Typically they were white single men in employment who on average had used 
methamphetamine more than every other day and had used for about 10 years. Over 8 
in 10 were on probation or parole and most had a history of physical and sexual abuse.
Main findings
Just half the 60 patients allocated to the protocol stayed in the study until the end of the 
40-day medication phase and 18 to the end of the study. Corresponding figures for 
placebo patients were 42 and 26. At no point (until the end of the medication infusion 
phase, of all medication, or of the study) were there any statistically significant 
differences between PROMETATM and placebo patients in the proportions of weekly urine 
tests which indicated no methamphetamine use, or in the proportions of patients with 
three consecutive methamphetamine-free tests. Proportions of methamphetamine-free 
urine tests increased over the course of the study, but to the same degree regardless of 
whether the active protocol was administered or a placebo.
This general picture was replicated by the patients' own accounts of their 
methamphetamine use, by the end of the study among retained patients averaging just 
four to five days a month, regardless of whether real mdeication had been taken. Craving 
for methamphetamine too fell roughly equally over the course of the study and retention 
or compliance with taking medication did not significantly differ. Safety concerns were 
few. No adverse occurrences or experiences were deemed definitely related to the study 
drugs, and only one was probably related.
The authors' conclusions
Under the conditions of this study, treatment with the combination medication protocol 
was no more effective than placebo in reducing methamphetamine use or craving or 
keeping patients in treatment. The results were negative and clear: active medication 
and placebo groups showed no statistically significant differences in drug use as 
measured by urine testing or self-report, or in self-reported craving. Both groups 
substantially reduced their reported methamphetamine use. The placebo group remained 
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in the study for on average about 17 days longer than the medication group, not a 
statistically significant difference after age had been taken in to account. There were no 
clinically relevant differences in the pattern or severity of adverse events that would 
imply a greater risk in either group.
These findings differ from those of another randomised and placebo-controlled trial of a 
similar medication combination, which did find reductions in methamphetamine use 
associated with the protocol. A possible explanation could be the influence of the 
marketing campaign which occurred during the featured trial, which may have elevated 
the placebo effect. Inpatient hospitalisation for infusion at two of the sites may have also 
contributed to a strong placebo effect. Consistent with this explanation, at the end of 
treatment at one of the clinics twice as many patients believed they had received active 
medication as believed they had received a placebo. Regardless of whether they actually 
did receive active medication, these patients were twice as likely to be abstinent at the 
end of the study. Perhaps too the psychosocial components of the treatment were 
stronger in the featured study.
 These findings, which do not even hint at a positive impact from a (in the 
USA) fairly widely implemented treatment, represent another blow to attempts to find 
pharmacological solutions to dependence on stimulant drugs. At the same time, among 
the minority of patients who stayed in the study to be assessed, they are a testament to 
the power of the patient's desire to get better and the impact of psychological and social 
influences – in particular, the belief that they are receiving a treatment which works, 
even if in reality it is an inactive placebo.
The more positive earlier trial referred to by the authors lasted just 30 days, and even 
then, by the end the gains associated with the active medication had nearly evaporated. 
In the final week patients who had received active medication said they had used 
methamphetamine on 41% of days, those given placebo, 44%, a minimal difference. 
After day six of the trial urine test results did not significantly differ between the two sets 
of patients. The report on the study says it was "double-blind', presumably meaning that 
both investigators and patients did not know which patient was in which group, but how 
blinding was achieved is not detailed, nor whether it successfully hid who got what, and 
whether medical staff too were blinded is unclear. From the featured study, it seems that 
anything which enabled patients to deduce or guess whether they had been given active 
medication could have accounted for the positive results. Possibly too, the fact that in the 
featured study the great majority of patients were under criminal justice supervision gave 
those who could get better such a strong incentive to do so that the drugs made no 
further difference. How many might have been in this position in the earlier trial was not 
reported.
The one seizure in the featured study is consistent with the warning from a commentator 
on the study that "the adverse effects of this medication combination, especially the risk 
of seizures associated with flumazenil, merits caution, especially in view of the frequent 
comorbidity of seizures in methamphetamine users".
The evaluated protocol has been the subject of considerable controversy in the USA. Attempts have also been 
made to gain a foothold in the UK. The confidential protocol is marketed by a US healthcare services 
management company which does not manufacture or distribute the medications. Rather than a new drug, it 
combines in what the company describes as "a unique dosing algorithm" several medications approved by US 
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authorities, but not for the treatment of substance dependence. According to the company, the treatment 
programme it markets which features the protocol is "the only outpatient program to uniquely combine medical 
and psychosocial therapy into one integrated program". Apparently the company changed its name (1 2) in 
March 2011 from Hythiam to Catasys which now markets a similar treatment under the trade name OnTrakTM. 
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